hims hers glp 1 & stock drops 30% after Novo Nordisk terminates deal Hims & Hers swings to

Of the 14 PDPs available to the average beneficiary in 2025, 12 are national PDPs (available in all 34 PDP regions nationwide) (Appendix Table 1)

doi: 10.1016/j.bbrc.2018.10.197 66 WuXLiSXuePLiY

[DOI] [PMC free article] [PubMed] [Google Scholar] 169.Carls G.S., Tuttle E., Tan R.D., Huynh J., Yee J., Edelman S.V

Niazi explains that tirzepatide is a newer dual-agonist that targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which he says offers superior metabolic regulation and appetite suppression. Mounjaro is currently FDA-approved for type 2 diabetes, and Zepbound is also FDA-approved for weight loss